Header cover image

U.S. Pharmaceuticals & Biotech Large Cap High Growth Potential

UPDATED Sep 22, 2022

Large Cap Companies that analysts expect to have high earnings, revenue or cash flow growth in the next 3 years.

15 companies
CompanyLast Price7D Return1Y ReturnMarket CapAnalysts TargetValuationGrowthDiv Yield
RPRXRoyalty PharmaUS$41.06-2.6%10.6%US$24.9bUS$53.95PE38.5xE54.5%1.9%
ALNYAlnylam PharmaceuticalsUS$202.71-2.8%8.4%US$24.3bUS$237.77PS27.5xE70.0%n/a
INCYIncyteUS$67.41-2.3%-3.4%US$15.0bUS$88.47PE15.9xE30.0%n/a
SGENSeagenUS$140.55-0.5%-15.4%US$25.9bUS$183.43PS14.6xE74.9%n/a
LLYEli LillyUS$310.870.5%33.9%US$295.4bUS$335.71PE51.9xE21.9%1.3%
ILMNIlluminaUS$193.49-4.2%-55.3%US$30.4bUS$251.56PS6.5xE69.1%n/a
HZNPHorizon TherapeuticsUS$62.63-1.4%-42.8%US$14.4bUS$105.64PE18.9xE25.6%n/a
BMYBristol-Myers SquibbUS$71.29-0.7%17.6%US$152.2bUS$80.32PE23xE22.1%3.0%
IQVIQVIA HoldingsUS$190.62-8.1%-27.3%US$35.6bUS$269.11PE30.6xE18.4%0%
BMRNBioMarin PharmaceuticalUS$84.92-3.6%7.1%US$15.8bUS$114.14PE291.3xE47.9%n/a
TECHBio-TechneUS$290.22-8.3%-45.9%US$11.4bUS$473.45PE41.8xE10.8%0.4%
RGENRepligenUS$189.94-18.2%-41.4%US$10.5bUS$266.56PE66.1xE18.4%n/a
BIOBio-Rad LaboratoriesUS$418.55-11.5%-47.5%US$12.4bUS$705.00PS4.3xE81.1%n/a
ZTSZoetisUS$149.46-6.1%-27.0%US$70.0bUS$225.64PE33.5xE10.5%0.9%
ICLRICONUS$191.02-8.5%-32.1%US$15.6bUS$267.57PE74.2xE29.4%n/a
Page 1 of 1